European Journal of Clinical Pharmacology

, Volume 30, Issue 5, pp 559–565 | Cite as

The effect of bucindolol on the airway function of asthmatics

  • R. E. Ruffin
  • A. J. Crockett
  • J. H Alpers


The airway and cardiovascular effects of separate single oral doses of 50, 100 and 200 mg of bucindolol were compared to those of placebo in a double-blind trial in 16 patients with mild to moderately severe asthma. Heart rate (HR), blood pressure (BP), forced vital capacity (FVC), forced expired volume in one second (FEV1), maximum expiratory flow at 50% of vital capacity (FEF50) and maximum expiratory flow at 75% of expired vital capacity (FEF75) were measured before and at intervals for 4 h, when salbutamol (200 µg) was inhaled and the measurements repeated 15 min later. There was an interval of at least 4 days between each drug treatment day.

Four of the 16 patients developed clinically significant bronchoconstriction with 50 mg (3) or 100 mg (1) of bucindolol and were withdrawn from the study. The remaining patients showed impaired bronchodilator response to salbutamol for each bucindolol dose as compared to placebo. No significant BP or HR effects were measured. Two patients withdrew because of circumstances unrelated to bucindolol induced bronchoconstriction. The development of bucindolol induced bronchoconstriction in this group of mild to moderate asthmatics was not predicted by the level of baseline pulmonary function, or the level of histamine responsiveness. However, there was a weak relationship between bucindolol induced bronchoconstriction and salbutamol induced bronchodilation. There was no definitive asthmatic characteristic to predict the likelihood of significant bucindolol induced bronchoconstriction in this asthmatic population.

Key words

bucindolol asthma bronchoconstriction airway function histamine responsiveness bronchodilator responsiveness 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Deitchman D, LaBudde JA, Seidehamel RJ (1983) Bucindolol. In: Scriabine (ed) New drugs annual: Cardiovascular drugs. Raven Press, New York, pp 1–18Google Scholar
  2. 2.
    McNeill RS (1964) Effect of a β-adrenergic blocking agent, propranolol, on asthmatics. Lancet 2: 1101–1102Google Scholar
  3. 3.
    Welsh PW, Reed CE, Jackson LJ, Seidenhamel RJ (1985) Effect of two beta-agonists, bucindolol and metoprolol, on pulmonary function in subjects with asthma. J Allergy Clin Immunol 75: 181 (Abs)Google Scholar
  4. 4.
    Leff AR, Garrity ER, Munoz NM, Tallet J, Cavigelli M, Deitchman D, Rajfer SI (1984) Selectivity of the intrinsic sympathomimetic activity of the β-adrenergic blocking drug bucindolol. J Cardiovasc Pharmacol 6: 859–866Google Scholar
  5. 5.
    Ruffin RE, McIntyre ELM, Latimer KM, Ward HE, Crockett AJ, Alpers JH (1982) Assessment of β-adrenoreceptor antagonists in asthmatic patients. Br J Clin Pharmacol 13: 325S-335SGoogle Scholar
  6. 6.
    Morris JF, Koski A, Johnson LC (1971) Spirometric standards for healthy non-smoking adults. Am Rev Respir Dis 103: 57–67Google Scholar
  7. 7.
    Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE (1977) Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 7: 235–243Google Scholar
  8. 8.
    Snedecor EW, Cochran WG (1967) Statistical methods, 6th edn. Iowa State University Press, Ames, IowaGoogle Scholar
  9. 9.
    Maury M, Berdeaux A, Kher A, Duhaze P, Guidicelli JF (1985) Comparative β-adrenoreceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man. Eur J Clin Pharmacol 27: 649–656Google Scholar
  10. 10.
    Gill JS, Beevers DG (1984) Bucindolol: Effects on blood pressure, airways resistance and creatine phosphokinase. Eur J Clin Pharmacol 27: 265–268Google Scholar
  11. 11.
    Rowland M (1972) Drug administration and regimens. In: Melmon KL, Morelli H, Fred (eds) Clinical pharmacology. Basic principles in therapeutics. Macmillan Publishing, New YorkGoogle Scholar
  12. 12.
    Bouhuys A (1974) Breathing. Physiology, environment and lung disease. Grune and Stratton, New York, London, p 324Google Scholar
  13. 13.
    Benson MK (1975) Bronchial hyperreactivity. Br J Dis Chest 69: 227–239.6Google Scholar
  14. 14.
    Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE (1977) Protective effect of drugs on histamine-induced asthma. Thorax 32: 429–437Google Scholar
  15. 15.
    Thiringer B, Svedmyr N (1976) Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics. Eur J Clin Pharmacol 10: 163–170Google Scholar
  16. 16.
    Ruffin R, Alpers J, Henderson G, Crockett A, MacLean A (1984) Effect of varying plasma concentrations of beta-blockers on the airway function of asthmatics. Aust NZ J Med 14: 533–534 (abs)Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • R. E. Ruffin
    • 1
  • A. J. Crockett
    • 1
  • J. H Alpers
    • 1
  1. 1.Department of MedicineFlinders Medical CentreBedford ParkAustralia

Personalised recommendations